Literature DB >> 2665688

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia.

R Tandon1, J F Greden.   

Abstract

Despite renewed interest in negative schizophrenic symptoms, the pathophysiological mechanisms involved in their development remain obscure. Although the cholinergic system has been implicated in schizophrenia, it has not been accorded a major role in current theories of pathophysiology. We present evidence from several lines of research that suggests that muscarinic hyperactivity may be implicated in the pathogenesis of negative schizophrenic symptoms. Specifically, cholinergic overdrive leads to a behavioral syndrome strikingly similar to the negative schizophrenic syndrome, anticholinergic agents may alleviate negative symptoms, schizophrenic patients with negative symptoms tend to "abuse" anticholinergics, and polysomnographic, neuroendocrine, and other pharmacological findings appear to be generally consistent with this hypothesis. The hypothesis is testable and is presented as a heuristic model that focuses on the dynamic interplay between cholinergic and dopaminergic systems in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2665688     DOI: 10.1001/archpsyc.1989.01810080075010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  22 in total

Review 1.  Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies.

Authors:  Jim R Fadel
Journal:  Behav Brain Res       Date:  2010-02-16       Impact factor: 3.332

2.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

3.  Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.

Authors:  Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2008-09-20       Impact factor: 3.575

Review 4.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

Review 5.  Neuropharmacology of attention.

Authors:  Joshua A Burk; Sarah A Blumenthal; Eden B Maness
Journal:  Eur J Pharmacol       Date:  2018-08-06       Impact factor: 4.432

6.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 7.  Classics in Chemical Neuroscience: Aripiprazole.

Authors:  Austen B Casey; Clinton E Canal
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

8.  Sleep in depression: the influence of age, gender and diagnostic subtype on baseline sleep and the cholinergic REM induction test with RS 86.

Authors:  D Riemann; F Hohagen; M Bahro; M Berger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

9.  Dopamine modulates the responsivity of mediodorsal thalamic cells recorded in vitro.

Authors:  A Lavin; A A Grace
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

Review 10.  Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin?

Authors:  M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.